Outcomes of the addition of oral administration of curcumin-phospholipid to hyaluronic acid-based tear substitute for the treatment of dry eye disease
The aim of this study is to report the clinical outcomes of oral supplementation with curcumin-phospholipid in addition to hyaluronic acid-based tear substitute for the management of dry eye disease (DED). Patients with a diagnosis of DED confirmed by pathological values of both NIKBUT <10 s....
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-10-01
|
| Series: | Frontiers in Ophthalmology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fopht.2023.1236525/full |
| _version_ | 1797665758830919680 |
|---|---|
| author | Massimiliano Borselli Fausto F. Ferrari Pietro Bianchi Costanza Rossi Giovanna Carnovale Scalzo Domenica Mangialavori Vincenzo Scorcia Giuseppe Giannaccare |
| author_facet | Massimiliano Borselli Fausto F. Ferrari Pietro Bianchi Costanza Rossi Giovanna Carnovale Scalzo Domenica Mangialavori Vincenzo Scorcia Giuseppe Giannaccare |
| author_sort | Massimiliano Borselli |
| collection | DOAJ |
| description | The aim of this study is to report the clinical outcomes of oral supplementation with curcumin-phospholipid in addition to hyaluronic acid-based tear substitute for the management of dry eye disease (DED). Patients with a diagnosis of DED confirmed by pathological values of both NIKBUT <10 s. and OSDI Questionnaire score > 12 were included. Patients were randomized to receive 2 different treatments: 0.25% hyaluronic acid-based tear substitute 3 time daily (Group 1) or as above plus curcumin-phosphatidylcholine complex tablets once a day (Group 2). Patients were evaluated at baseline (T0) and after 90 days of treatment (T1) by means of Keratograph for the measurement of NIKBUT, TMH, meibomian gland dropout and bulbar redness. Overall, data from 90 eyes of 45 patients were included. Group 1 consisted of 48 eyes of 24 patients, while group 2 included 42 eyes of 21 patients. When comparing median values of both groups at T0, no statistically significant differences were found for all parameters; instead for T1, statistically significant differences were found for redness and OSDI compared to Group 1. In group 1, a statistically significant reduction after the treatment was detected for Nikbut average and OSDI questionnaire; while in group 2, a statistically significant reduction after treatment was recorded for Nikbut average, bulbar redness and OSDI questionnaire. The addition of an oral supplement containing curcumin-phospholipid may help in a greater improvement of bulbar redness and subjective ocular symptoms compared to the treatment with tear substitutes alone for the management of DED. |
| first_indexed | 2024-03-11T19:49:27Z |
| format | Article |
| id | doaj.art-749637ffb1df4c5281ca1fd432559617 |
| institution | Directory Open Access Journal |
| issn | 2674-0826 |
| language | English |
| last_indexed | 2024-03-11T19:49:27Z |
| publishDate | 2023-10-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Ophthalmology |
| spelling | doaj.art-749637ffb1df4c5281ca1fd4325596172023-10-05T13:22:29ZengFrontiers Media S.A.Frontiers in Ophthalmology2674-08262023-10-01310.3389/fopht.2023.12365251236525Outcomes of the addition of oral administration of curcumin-phospholipid to hyaluronic acid-based tear substitute for the treatment of dry eye diseaseMassimiliano BorselliFausto F. FerrariPietro BianchiCostanza RossiGiovanna Carnovale ScalzoDomenica MangialavoriVincenzo ScorciaGiuseppe GiannaccareThe aim of this study is to report the clinical outcomes of oral supplementation with curcumin-phospholipid in addition to hyaluronic acid-based tear substitute for the management of dry eye disease (DED). Patients with a diagnosis of DED confirmed by pathological values of both NIKBUT <10 s. and OSDI Questionnaire score > 12 were included. Patients were randomized to receive 2 different treatments: 0.25% hyaluronic acid-based tear substitute 3 time daily (Group 1) or as above plus curcumin-phosphatidylcholine complex tablets once a day (Group 2). Patients were evaluated at baseline (T0) and after 90 days of treatment (T1) by means of Keratograph for the measurement of NIKBUT, TMH, meibomian gland dropout and bulbar redness. Overall, data from 90 eyes of 45 patients were included. Group 1 consisted of 48 eyes of 24 patients, while group 2 included 42 eyes of 21 patients. When comparing median values of both groups at T0, no statistically significant differences were found for all parameters; instead for T1, statistically significant differences were found for redness and OSDI compared to Group 1. In group 1, a statistically significant reduction after the treatment was detected for Nikbut average and OSDI questionnaire; while in group 2, a statistically significant reduction after treatment was recorded for Nikbut average, bulbar redness and OSDI questionnaire. The addition of an oral supplement containing curcumin-phospholipid may help in a greater improvement of bulbar redness and subjective ocular symptoms compared to the treatment with tear substitutes alone for the management of DED.https://www.frontiersin.org/articles/10.3389/fopht.2023.1236525/fullcurcumindry eye diseaseocular surfacetear substitutestear film |
| spellingShingle | Massimiliano Borselli Fausto F. Ferrari Pietro Bianchi Costanza Rossi Giovanna Carnovale Scalzo Domenica Mangialavori Vincenzo Scorcia Giuseppe Giannaccare Outcomes of the addition of oral administration of curcumin-phospholipid to hyaluronic acid-based tear substitute for the treatment of dry eye disease Frontiers in Ophthalmology curcumin dry eye disease ocular surface tear substitutes tear film |
| title | Outcomes of the addition of oral administration of curcumin-phospholipid to hyaluronic acid-based tear substitute for the treatment of dry eye disease |
| title_full | Outcomes of the addition of oral administration of curcumin-phospholipid to hyaluronic acid-based tear substitute for the treatment of dry eye disease |
| title_fullStr | Outcomes of the addition of oral administration of curcumin-phospholipid to hyaluronic acid-based tear substitute for the treatment of dry eye disease |
| title_full_unstemmed | Outcomes of the addition of oral administration of curcumin-phospholipid to hyaluronic acid-based tear substitute for the treatment of dry eye disease |
| title_short | Outcomes of the addition of oral administration of curcumin-phospholipid to hyaluronic acid-based tear substitute for the treatment of dry eye disease |
| title_sort | outcomes of the addition of oral administration of curcumin phospholipid to hyaluronic acid based tear substitute for the treatment of dry eye disease |
| topic | curcumin dry eye disease ocular surface tear substitutes tear film |
| url | https://www.frontiersin.org/articles/10.3389/fopht.2023.1236525/full |
| work_keys_str_mv | AT massimilianoborselli outcomesoftheadditionoforaladministrationofcurcuminphospholipidtohyaluronicacidbasedtearsubstituteforthetreatmentofdryeyedisease AT faustofferrari outcomesoftheadditionoforaladministrationofcurcuminphospholipidtohyaluronicacidbasedtearsubstituteforthetreatmentofdryeyedisease AT pietrobianchi outcomesoftheadditionoforaladministrationofcurcuminphospholipidtohyaluronicacidbasedtearsubstituteforthetreatmentofdryeyedisease AT costanzarossi outcomesoftheadditionoforaladministrationofcurcuminphospholipidtohyaluronicacidbasedtearsubstituteforthetreatmentofdryeyedisease AT giovannacarnovalescalzo outcomesoftheadditionoforaladministrationofcurcuminphospholipidtohyaluronicacidbasedtearsubstituteforthetreatmentofdryeyedisease AT domenicamangialavori outcomesoftheadditionoforaladministrationofcurcuminphospholipidtohyaluronicacidbasedtearsubstituteforthetreatmentofdryeyedisease AT vincenzoscorcia outcomesoftheadditionoforaladministrationofcurcuminphospholipidtohyaluronicacidbasedtearsubstituteforthetreatmentofdryeyedisease AT giuseppegiannaccare outcomesoftheadditionoforaladministrationofcurcuminphospholipidtohyaluronicacidbasedtearsubstituteforthetreatmentofdryeyedisease |